Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03301467 · ClinicalTrials.gov registry record · Phase 2
Controlled Trial Evaluating Avacopan in C3 Glomerulopathy
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
NCT03301467 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 57 participants.
The verdict
NCT03301467, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
Study Summary
The aim of this trial is to evaluate the effect of avacopan treatment on renal disease activity in patients with complement component 3 glomerulopathy (C3G). Funding Source - FDA OOPD
Interventions
- DRUG Avacopan
- DRUG Avacopan Matching Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2017-09-29 |
| Est. Completion | 2021-10-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03301467
The ClinicalTrials.gov registry entry for NCT03301467 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Avacopan is the first listed.
NCT03301467 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03301467 about?
NCT03301467 is a clinical study titled "Controlled Trial Evaluating Avacopan in C3 Glomerulopathy". The aim of this trial is to evaluate the effect of avacopan treatment on renal disease activity in patients with complement component 3 glomerulopathy (C3G). Funding Source - FDA OOPD
What is the current status of trial NCT03301467?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2017-09-29. Estimated completion is 2021-10-27.
What interventions are being tested in trial NCT03301467?
The interventions under investigation include: Avacopan (DRUG), Avacopan Matching Placebo (DRUG).
Who is sponsoring clinical trial NCT03301467?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.